1st Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

Firm
Client
Income
—
Expenses
$490,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Issues related to Section 700 (Champus provisions) of the annual National Defense Authorization Act for 2012

LobbyistCovered position, as disclosed
NANCY GILBRIDE —
JONAH C HOUTS —
MARY M ROSADO —

Contacted: Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); White House Office; Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Executive Office of the President (EOP); Internal Revenue Service (IRS); Federal Trade Commission (FTC); Government Accountability Office (GAO); Defense, Dept of (DOD); Labor, Dept of (DOL); SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

HR 4, Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011 Regulatory implementation of various tax provisions in the health reform legislation Repeal of the 3% tax withholding requirement for federal contractors

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); White House Office; Defense, Dept of (DOD); Internal Revenue Service (IRS); Government Accountability Office (GAO); Centers For Disease Control & Prevention (CDC); Congressional Budget Office (CBO); SENATE; Federal Trade Commission (FTC); Executive Office of the President (EOP)

Bills named: H.R. 4 (112th)

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH FDA issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs)

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC); Internal Revenue Service (IRS); Government Accountability Office (GAO); Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); SENATE; Executive Office of the President (EOP); Labor, Dept of (DOL); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); White House Office; Federal Trade Commission (FTC)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General regulatory changes and legislative issues that impact the Part D program such as EGWP waivers and MTM expansion (HR 891/S 274). Statutory implementation of changes to the definition of Average Manufacture Price in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price (HR 905/S 733).

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: SENATE; Congressional Budget Office (CBO); Defense, Dept of (DOD); Government Accountability Office (GAO); Executive Office of the President (EOP); Internal Revenue Service (IRS); Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Federal Trade Commission (FTC); Health & Human Services, Dept of (HHS); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Centers For Medicare and Medicaid Services (CMS); White House Office

Bills named: H.R. 891 (112th), H.R. 905 (112th)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (essential health benefits, grandfathering, value-base insurance design, Rx quality, electronic prescribing, PBM disclosure requirements, medical loss ratio); legislation to promote generic drugs; regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; Zadroga implement.

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Government Accountability Office (GAO); Health & Human Services, Dept of (HHS); Health Resources & Services Administration (HRSA); Centers For Disease Control & Prevention (CDC); Centers For Medicare and Medicaid Services (CMS); SENATE; Internal Revenue Service (IRS); Federal Trade Commission (FTC); Executive Office of the President (EOP); HOUSE OF REPRESENTATIVES; Defense, Dept of (DOD); Labor, Dept of (DOL); Congressional Budget Office (CBO); White House Office

Bills named: H.R. 979 (112th)

Labor Issues/Antitrust/Workplace LBR

HR 1409, Legislation to exempt health care providers (including pharmacies) from the antitrust laws for purposes of negotiating with payers.

LobbyistCovered position, as disclosed
JONAH C HOUTS —
ROBERT W LIVELY —
MARY M ROSADO —

Contacted: Federal Trade Commission (FTC); Executive Office of the President (EOP); Congressional Budget Office (CBO); White House Office; Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Centers For Disease Control & Prevention (CDC); SENATE; Defense, Dept of (DOD); Internal Revenue Service (IRS)

Bills named: H.R. 1409 (112th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.